CONTINUING MEDICAL EDUCATION
Claim Your CME
Attendees of the 2018 Community Oncology Conference can claim continuing education credits by completing the survey at the following links. Please be sure to complete all the questions in order to receive your documentation of credit.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and Community Oncology Alliance. Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
Imedex, LLC designates this enduring activity for a maximum of 11.5 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
Successful completion of this CME activity enables a participant to earn up to 11.5 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for granting ABIM MOC Points.
ABIM Diplomates will have 60 days from the conclusion of the conference (deadline is 6/12/2018) to claim MOC points and must be able to provide to Imedex the correct ID number, DOB (MM/DD) and name as registered at ABIM.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the American Nurses Credentialing Center (ANCC) through the joint providership of North American Center for Continuing Medical Education, LLC (NACCME), Imedex and the Community Oncology Alliance. The North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This continuing nursing education activity awards 11.5 contact hours
Provider approved by the California Board of Registered Nursing, Provider #13255 for 11.0 contact hours.
Imedex, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This knowledge activity (0408-9999-18-001-L01-P) has been approved for a maximum of 11.5 contact hours (1.15 CEUs). To receive credit, participants must complete an activity evaluation survey. In order to claim credit in a timely matter, you must submit your evaluation and credit request within 60 days (deadline is Jun 12, 2018).
Pharmacists must be able to provide their correct NABP number and DOB (MM/DD). Imedex is responsible for submitting data through CPE Monitor.
Processing of Certificates
After the conference, participants will be emailed a link from the Imedex Office of CME (officeofcme@Imedex.com) with instructions regarding claiming credit, contact hours, or to request a certificate of participation. We will not be issuing certificates of credit or certificates of participation onsite.
Who Should Attend/Target Audience
This educational activity is designed to meet the educational needs of US-based community oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with cancer.
Learning Objectives – Physicians & Nurses
After successfully completing this continuing medical education activity, clinicians should be able to:
- Extrapolate data portending the potential economic impact of biosimilars in cancer care
- Assess recent advances and emerging data for new treatments for HR+, HER2+, and triple-negative breast cancer
- Devise a strategy to integrate immune checkpoint inhibitors into your treatment plans for appropriately selected patients with head and neck and lung cancers
- Explain the immunotherapeutic process of CAR-T for the treatment of both adults and children with hematologic malignancies
- Analyze genomic molecular profiling and its search for better biomarkers for immunotherapy
- Describe the new role of immune checkpoint inhibitors in the treatment of head and neck cancer
- List recent advances in the treatment of multiple myeloma
- Appraise the increasing financial aspects of cancer care and its impact on care affordability and delivery
- Debate the evolving political landscape of cancer care and its effects on patient advocacy
- Identify multiple new treatments for lung cancer that were approved in 2017, including targeted treatments for specific mutations and an immunotherapy + chemotherapy combination
- Evaluate the new standard of care treatment for ALK-positive NSCLC
Learning Objectives – Pharmacy
At the completion of this activity, pharmacists should be able to better:
- Identify advances in treatments for HR+, HER2+, and triple-negative breast cancer, multiple myeloma, head and neck cancer, and non-small cell lung cancer
- Evaluate the evolving role of biosimilar agents in oncology treatment plans
- Formulate a plan to provide oncology agents in a manner that is both efficacious and financially responsible
- Describe aspects of the evolving political landscape affecting oncology pharmacy
The following companies have provided an educational grant in support of this conference:
Astellas Celgene Kite Merck Novartis Pfizer Takeda Oncology
The Commercial Exhibition
As a part of the conference, companies and organizations may display their products and services. The exhibition is located in Potomac CD/1-6 and Potomac AC Lobby. Exhibitions should not be construed as an endorsement of a product or manufacturer’s claims by Imedex.
As an accredited provider of continuing medical education, Imedex, LLC requires anyone in a position to affect the activity’s subject matter to disclose any financial relationships they have as related to the contents of their presentations. The existence of commercial or financial interests of presenters related to the subject matter of their presentations should not be construed as implying bias or decreasing the value of their presentations. However, disclosure should help participants form their own judgments.
All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial interests with the entities who produce, market, re-sells or distributes products or services used on or by patients, to which they may refer, are listed below.
The following individuals have reported the following relevant financial relationships:
Miriam Atkins, MD: Consultant – Pruitt Hospice; Advisory Board – Integra
Betty Apt: Travel Support – Community Oncology Alliance (COA)
Jesus G. Berdeja, MD: Research/Grant Support – Abbvie, Amgen, Bluebird, Teva, Celgene, Genentech, Glenmark, Janssen, Novartis, Poseida
Joshua H. Bilenker, MD: Stock Holder – Loxo Oncology & Aisling Capital
Sibel Blau, MD: Employee – All4Care (Spouse); Consultant – BMS, The American Journal of Managed Care
Sean Callinicos: Employee – Employee, Cardinal Health; Stockholder – Cardinal Health
Michael Diaz, MD: Consultant – Janssen
David Eagle, MD: Speaker, travel support – ION
Mark Fendrick, MD: Consultant – AbbVie, Amgen, Bayer, Centivo, Community Oncology Association, Exact Sciences, Freedman Health, Lilly, Mallinckrodt, MedZed, Merck, Risalto, Sempre Health, State of Minnesota,
Takeda, Wellth, Zansors. Research – AHRQ, Boehringer-Ingelheim, Gary & Mary West Health Policy Center, Laura & John Arnold Foundation, National Pharmaceutical Council, PCOR, PhRMA, RWJ Foundation, State of Michigan/CMS. Partner at V-BID Health, LLC.
Bo Gamble: Speakers’ Bureau – Merck
Lucio Gordan, MD: Consultant/Speakers’ Bureau – Myriad Genetics; Employee – AmerisourceBergen
Bruce Gould, MD: Advisory Board – Heron, Sanofi; Employee – Amgen, Genentech
Amanda Hodges BSN, RN, OCN: Travel Support: Community Oncology Alliance (COA)
Houston Holmes, MD, MBA, FACP: Consultant – Jannssen, Rigel, Bayer; Speakers’ Beareau – Kite, Seattle Genetics; Research/Grant Support – Kite, Seattle Genetics, Juno, Unum Therapeutics, Infinity Pharmacology; Other – Infinity Pharmacology
Susanne Johnson-Berns, BSA, GGCP – Consultant/Advisory Board: Abbvie
Ben Jones: Stock Holder – McKesson Corp.
Richard Kane, MA, MPP: Stock Holder – Inovalon
Shaji Kumar, MD: Research/Grant Support/Advisory Board – Takeda, Celgene, Janssen
Chris Mancill, MA: Stock Holder – Amgen
Stacey McCullough, PharmD: Consultant – Heron, Novartis, Bayer, Regeneron, Teva; Other – American Journal of Managed Care
Jeff Mortier: Consultant – Community Oncology Alliance, Genentech, Johnson & Johnson, AstraZeneca, and Heron
Diane O’Keefe: Consultant – Apobiologix
Joyce O’Shaughnessy: Consultant – AstraZeneca, Novartis, Pfizer, Lilly, Celgene. Speakers’ Bureau – AstraZeneca. Travel Support – AstraZeneca, Novartis, Pfizer, Lilly, Celgene. Advisory Board – AstraZeneca, Novartis, Pfizer, Lilly, Celgene.
Ray Page, DO, PhD: Consultant – Cardinal Medical Source
Kavita K. Patel, MD, MS: Consultant/Travel Support – Evicore, NORC, BMS, PhRma; Stock Holder – Tesaro
Debra Patt, MD, MPH, MBA: (Spouse) Employee –Mednax
Jeff Patton, MD: Consultant – Amgen, Celgene, Herron, OrthoBiotech, BMS, Genentech, Cardinal Health
Terry Purdam: Travel Support – COA
Alti Rahman, MHA, MBA, CSSBB: Consultant – Merck
Robert M. Rifkin, MD, FACP: Advisory Board – Amgen, Celgene, Pfizer, EMD Serona; Stock Holder – McKesson Corp.
Byron C. Scott, MD, MBA: Other – UMass Amherst Isenberg School of Management
Patricia M Tubiak: Advisory Board – Community Oncology Alliance (COA)
Robert Twillman, PhD: Consultant – Millennium Health; Other – Miller Medical Communications
Jeffrey Vacirca, MD: Consultant/Advisory Board/Travel Support – ION
The following individuals indicate that they have nothing to disclose:
Robert Baird, Jr., RN, MSA, CASC
Richard W. Childs, MD
Christian Downs, JD, MHA
Suanne Gersdorf, FACHE
Callie Hills, BSW
Deborah Y. Kamin
Rebecca A. Kirch
James H. Leach, MBS, CPMA®
Jonathan E. Levitt, Esq.
Tripp Logan, PharmD
Robert LoNigro, MD, MS
Janice Martin, RN, BSN, OCN
Kathy W. Oubre, MS
Sarah D. Ponder
Barry Russo, MBA
Anand Shah MD, MPH
Mark E. Thompson, MD
The following individuals have chosen not to submit a disclosure form. Continuing education credit will not be offered during their sessions.
Scott Gottlieb, MD
Imedex, LLC Staff Disclosure of Financial Relationships
All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:
Chris Bolwell owns shares of stock of GlaxoSmithKline.
Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.
Unapproved and Investigational Uses of Drugs and Devices
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the Food and Drug Administration (FDA) of the United States or European Medicines Agency (EMA). Participants are encouraged to consult the EMA-approved or FDA-approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed in this document are the opinions of the presenters and do not necessarily reflect the opinions of Imedex, LLC.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
©1993-2018 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Twitter: @ImedexCME | Facebook: /Imedex | LinkedIn: /company/Imedex